High purity crystalline forms of peptides Arg-Lys-Asp and Arg-Lys-Asp-Val, process for preparing them and pharmaceutical compositions containing them

High purity crystalline forms of peptides Arg-Lys-Asp and Arg-Lys-Asp-Val, process for preparing them and pharmaceutical compositions containing them

The present invention relates to a process for the preparation of high purity crystalline forms of peptides Arg-Lys-Asp and Arg-Lys-Asp-Val from crude, amorphous peptides Arg-Lys-Asp and Arg-Lys-Asp-Val. The process is characterized in that the crude, amorphous peptide Arg-Lys-Asp or peptide Arg-Lys...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: UBERHARDT, ILDIKO NEE FALUDI, NYEKI, OLGA, SCHON, ISTVAN DR, HAJOS, GYOE-RGY, UBERHARDT, TAMAS, PETER, IMRE, GAZDAG, MARIA DR, KOVACS, LAJOS, SZPORNY, LASZLO, DENES, LASZLO,DR, IVANYI, GEZA, MUCK, ZSUZSANNA NEE KEREPESI, LORANT, GIZELLA NEE MAREK
Format: Patent
Sprache:eng ; fre ; ger
Schlagworte:
CHEMISTRY
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC CHEMISTRY
PEPTIDES
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online-Zugang:Volltext bestellen
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:The present invention relates to a process for the preparation of high purity crystalline forms of peptides Arg-Lys-Asp and Arg-Lys-Asp-Val from crude, amorphous peptides Arg-Lys-Asp and Arg-Lys-Asp-Val. The process is characterized in that the crude, amorphous peptide Arg-Lys-Asp or peptide Arg-Lys-Asp-Val is allowed to stand at room temperature with 5 to 20 unit volume of an ethanolic solution containing 0.5 to 4.0% by volume of acetic acid and 5 to 25% by volume of water, wherein the volume unit is calculated for the mass unit of the material and mass unit relates to volume unit as g relates to ml, then the crystallized peptide is separated from the crystalline suspension, preferably after cooling. Pharmaceutical compositions containing the crystalline forms of these peptides are also described.